RT Journal Article
SR Electronic
T1 Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 409
OP 415
DO 10.21873/invivo.12718
VO 36
IS 1
A1 TAKAAKI ARIGAMI
A1 DAISUKE MATSUSHITA
A1 KEISHI OKUBO
A1 TAKAKO TANAKA
A1 KEN SASAKI
A1 YUSUKE TSURUDA
A1 YOSHIAKI KITA
A1 SHINICHIRO MORI
A1 HIROSHI KURAHARA
A1 YOSHIKAZU UENOSONO
A1 TAKAO OHTSUKA
YR 2022
UL http://iv.iiarjournals.org/content/36/1/409.abstract
AB Background/Aim: To investigate changes in post-progression chemotherapy (PPC) before and after nivolumab approval and determine their prognostic impact. Patients and Methods: A total of 146 patients with unresectable gastric cancer who had at least progressive disease after first- and/or second-line chemotherapy were retrospectively enrolled. Results: Among the 146 patients, 46 and 23 received ramucirumab and nivolumab, respectively. Moreover, 95 and 62 patients received PPC after first- and second-line chemotherapy, respectively. Group B (i.e., at least chemotherapy after nivolumab approval) had significantly higher proportions of patients receiving ramucirumab therapy, nivolumab therapy, and PPC after first- or second-line chemotherapy compared to group A (i.e., termination of chemotherapy before nivolumab approval). Group A had significantly poorer prognosis than group B. Multivariate analysis showed that age, number of distant metastatic sites, and ramucirumab therapy were independent prognostic factors. Conclusion: Changes in chemotherapeutic strategies, including PPC, might contribute to improved prognosis in patients with advanced gastric cancer.